Scientist, Biology  

Senior Associate Scientist / Principal Associate Scientist, Biology - Contractor

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

DEM Biopharma aims to develop immunotherapies that will trigger macrophages and myeloid cells to eliminate tumors by recognizing “don’t eat me” (DEM) and “eat me” (EM) signals on cancer cells. Healthy cells have cell-surface proteins that provide DEM signals to tell macrophages to not destroy those cells. Cancer cells also present DEM signals to avoid destruction by macrophages. DEM Biopharma is using their proprietary CHoMP (Co-culture with Human Myeloid Phagocytes) platform to identify unknown DEM and EM signals. The platform utilizes inter-cellular CRISPR screening in co-cultures of tumor cells, macrophages, and other immune cells. By identifying novel DEM and EM signals, DEM Biopharma hopes to expand the therapeutic potential of DEM/EM targeting.

<p>DEM Biopharma aims to develop immunotherapies that will trigger macrophages and myeloid cells to eliminate tumors by recognizing “don’t eat me” (DEM) and “eat me” (EM) signals on cancer cells. Healthy cells have cell-surface proteins that provide DEM signals to tell macrophages to not destroy those cells. Cancer cells also present DEM signals to avoid destruction by macrophages. DEM Biopharma is using their proprietary CHoMP (Co-culture with Human Myeloid Phagocytes) platform to identify unknown DEM and EM signals. The platform utilizes inter-cellular CRISPR screening in co-cultures of tumor cells, macrophages, and other immune cells. By identifying novel DEM and EM signals, DEM Biopharma hopes to expand the therapeutic potential of DEM/EM targeting.</p>


Find a biotech startup job.